Description of Collaborative Activity: |
An National Institute of Mental Health (NIMH) Program Officer (PO) was invited to serve as a voting ad hoc member of one of the Food and Drug Administration (FDA) Arthritis Drugs Advisory Committee, which met to review a new drug application for the treatment of Chronic Fatigue Syndrome (CFS). Subsequently, in FY2014 the NIMH PO was invited as the sole NIH representative to a follow-up meeting at the FDA, led by the Director of the FDA Center for Drug Evaluation and Research among FDA staff, a CDC representative, the sponsor, and patient/consumer representatives to discuss further steps in Myalgic Encephalomyelitis/CFS drug development. |
